Preface

The field of cancer research has witnessed a paradigm shift in recent decades, with metabolism emerging as a central theme in understanding tumor biology and therapeutic innovation. Cancer cells are not merely uncontrolled proliferators; they are highly adaptive entities that rewire metabolic pathways to sustain growth, evade immune surveillance, and resist therapy. This book, Targeted Oncometabolism: New Frontiers in Cancer Therapy, is designed to provide a comprehensive exploration of these metabolic intricacies and their translational potential in oncology.

The volume begins with foundational insights into cancer metabolism, tracing its historical evolution and highlighting the hallmarks of metabolic reprogramming. Early chapters examine glycolysis, glutamine metabolism, lipid biosynthesis, and nucleotide pathways, emphasizing how these processes are hijacked by malignant cells to fuel proliferation and survival. By integrating classical biochemistry with modern metabolomics, the book underscores the duality of metabolic pathways—both as drivers of tumor progression and as vulnerabilities that can be strategically targeted.

A distinctive feature of this work is its focus on the tumor microenvironment. Hypoxia, nutrient competition, stromal interactions, and immune modulation are presented as critical determinants of metabolic heterogeneity. The interplay between cancer cells and surrounding fibroblasts, macrophages, and endothelial cells is explored to reveal how metabolic coupling shapes tumor aggressiveness. This systems level perspective reinforces the idea that cancer metabolism is not confined to the malignant cell but is a dynamic, ecosystem wide phenomenon.

Equally important is the therapeutic dimension. The book surveys current and emerging strategies to target metabolic dependencies, including inhibitors of glycolysis, glutaminase, lipid synthesis enzymes, and modulators of redox balance. It highlights innovative approaches such as synthetic lethality, metabolic stress induction, and nanotechnology based delivery systems. Case studies and clinical trial data bridge the gap between laboratory discoveries and patient care, offering readers a translational roadmap.

Natural compounds and personalized medicine approaches are also given prominence. Chapters discuss how phytochemicals modulate signaling pathways, how metabolomics aids biomarker discovery, and how next generation sequencing and liquid biopsies are reshaping precision oncology. The integration of artificial intelligence, computational modeling, and single cell metabolomics is presented as a frontier for identifying metabolic vulnerabilities and predicting therapeutic outcomes.

This book is intended for a diverse readership researchers, clinicians, postgraduate students, and professionals in pharmaceutical sciences who seek a structured yet forward looking resource. By combining mechanistic insights with translational relevance, it aims to serve both as a reference and as a catalyst for new ideas.

We envision Targeted Oncometabolism not merely as a compilation of chapters but as a dialogue between disciplines. The contributors, drawn from academia and clinical practice, bring varied expertise that enriches the narrative. Their collective effort underscores a shared conviction: that understanding and manipulating cancer metabolism will unlock novel therapeutic frontiers and improve patient outcomes.

It is our hope that this volume will inspire readers to appreciate the elegance and complexity of metabolic reprogramming in cancer, while motivating them to contribute to the next generation of discoveries. As the field advances, the integration of metabolic science into oncology promises to transform cancer therapy from conventional cytotoxic approaches to precision guided interventions.